147 related articles for article (PubMed ID: 28520590)
1. Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.
Ben-Shlomo A; Cooper O
Curr Opin Endocrinol Diabetes Obes; 2017 Aug; 24(4):301-305. PubMed ID: 28520590
[TBL] [Abstract][Full Text] [Related]
2. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
Cooper O; Mamelak A; Bannykh S; Carmichael J; Bonert V; Lim S; Cook-Wiens G; Ben-Shlomo A
Endocrine; 2014 Jun; 46(2):318-27. PubMed ID: 24287797
[TBL] [Abstract][Full Text] [Related]
3. ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.
Liu X; Kano M; Araki T; Cooper O; Fukuoka H; Tone Y; Tone M; Melmed S
Endocrinology; 2015 Jan; 156(1):71-9. PubMed ID: 25375038
[TBL] [Abstract][Full Text] [Related]
4. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
Cooper O; Bonert VS; Rudnick J; Pressman BD; Lo J; Salvatori R; Yuen KCJ; Fleseriu M; Melmed S
J Clin Endocrinol Metab; 2021 Jan; 106(2):e917-e925. PubMed ID: 33150390
[TBL] [Abstract][Full Text] [Related]
5. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.
Vlotides G; Siegel E; Donangelo I; Gutman S; Ren SG; Melmed S
Cancer Res; 2008 Aug; 68(15):6377-86. PubMed ID: 18676863
[TBL] [Abstract][Full Text] [Related]
6. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.
Fukuoka H; Cooper O; Mizutani J; Tong Y; Ren SG; Bannykh S; Melmed S
Mol Endocrinol; 2011 Jan; 25(1):92-103. PubMed ID: 21106881
[TBL] [Abstract][Full Text] [Related]
7. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.
Biagetti B; Simò R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681905
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
10. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
11. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
12. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Liu M; Xu S; Wang Y; Li Y; Li Y; Zhang H; Liu H; Chen J
Oncotarget; 2016 Dec; 7(51):84951-84964. PubMed ID: 27825114
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
14. A new medical therapy for Cushing disease?
Wondisford FE
J Clin Invest; 2011 Dec; 121(12):4621-3. PubMed ID: 22105164
[TBL] [Abstract][Full Text] [Related]
15. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
16. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
18. Refractory lactotroph adenomas.
Urwyler SA; Karavitaki N
Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
20. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
Leung EL; Fan XX; Wong MP; Jiang ZH; Liu ZQ; Yao XJ; Lu LL; Zhou YL; Yau LF; Tin VP; Liu L
Antioxid Redox Signal; 2016 Feb; 24(5):263-79. PubMed ID: 26528827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
